Holen Sie sich die Stockscreener-App
20.50
0.44%
0.09
Handel nachbörslich:
20.37
-0.13
-0.63%
Schlusskurs vom Vortag:
$20.41
Offen:
$20.41
24-Stunden-Volumen:
499.43K
Relative Volume:
0.68
Marktkapitalisierung:
$2.31B
Einnahmen:
$461.26M
Nettoeinkommen (Verlust:
$-175.95M
KGV:
-12.76
EPS:
-1.607
Netto-Cashflow:
$-164.65M
1W Leistung:
+14.85%
1M Leistung:
+4.91%
6M Leistung:
-38.46%
1J Leistung:
-35.47%
1-Tages-Spanne:
$20.25
$20.70
1-Wochen-Bereich:
$17.52
$20.78
52-Wochen-Spanne:
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Firmenname
Zai Lab Limited Adr
Sektor
Branche
Telefon
862161632588
Adresse
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
20.50 | 2.30B | 461.26M | -175.95M | -164.65M | -1.607 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-21 | Eingeleitet | Macquarie | Outperform |
| 2021-10-12 | Eingeleitet | Bernstein | Mkt Perform |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-04-15 | Eingeleitet | Guggenheim | Buy |
| 2019-07-12 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
| 2019-01-29 | Eingeleitet | Credit Suisse | Outperform |
| 2018-11-21 | Eingeleitet | Jefferies | Buy |
| 2018-06-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Eingeleitet | JP Morgan | Neutral |
| 2017-10-16 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Zai Lab Limited Adr Aktie (ZLAB) Neueste Nachrichten
Yajing Chen Sells 5,199 Shares of Zai Lab (NASDAQ:ZLAB) Stock - defenseworld.net
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer - BioPharma APAC
Zai Lab Limited (9688.HK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited (ZLAB) stock price, news, quote and history - Yahoo Finance UK
Revenue per share of Zai Lab Ltd. Sponsored ADR – FWB:1ZL - TradingView
Zai Lab (NASDAQ:ZLAB) CFO Sells $106,007.61 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) Insider Sells $196,029.46 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 5,576 Shares - MarketBeat
Rafael Amado Sells 9,910 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Zai Lab (ZLAB) executive sells ADSs to cover tax after RSU vest - Stock Titan
Zai Lab Ltd (ADR) stock: China's biotech powerhouse eyes global gains - AD HOC NEWS
Zai Lab (ZLAB) CLO nets ADSs after RSU vesting and tax sale - Stock Titan
[144] Zai Lab Ltd SEC Filing - Stock Titan
Rafael Amado reports ADS sales for ZLAB (NASDAQ: ZLAB) - Stock Titan
9,614 ADS tied to vesting listed by ZLAB (NASDAQ: ZLAB) with Fidelity broker - Stock Titan
Insider sells ZLAB (NASDAQ: ZLAB) ADS — Form 144 lists 4,194 shares - Stock Titan
Affiliate sale notice: ZLAB (NASDAQ: ZLAB) up to 5,199 ADS - Stock Titan
Zai Lab (NASDAQ:ZLAB) Trading 9.5% HigherStill a Buy? - MarketBeat
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy - ChartMill
KeyCorp (NYSE:KEY) Price Target Cut to $24.00 by Analysts at Morgan Stanley - Defense World
Hesai Group Sponsored ADR (NASDAQ:HSAI) Given Consensus Rating of “Buy” by Brokerages - Defense World
Hennes & Mauritz AB (OTCMKTS:HNNMY) Given Average Recommendation of “Hold” by Brokerages - Defense World
HBT Financial, Inc. (NASDAQ:HBT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
BTC Capital Management Inc. Lowers Holdings in Verizon Communications Inc. $VZ - Defense World
Constellation Software Inc. (OTCMKTS:CNSWF) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
The Goldman Sachs Group Issues Positive Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - Defense World
KANZHUN LIMITED Sponsored ADR (NASDAQ:BZ) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Precision Drilling Corporation (NYSE:PDS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Sees Large Growth in Short Interest - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap UpShould You Buy? - MarketBeat
Zai Lab (09688.HK) Narrows Loss to USD176 Million Last Year - AASTOCKS.com
Virtus Biotech ETF Holdings - Quiver Quantitative
Richard Gaynor Acquires 1,731 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Zai Lab (ZLAB) director adds 1,731 ADS in Rule 10b5-1 purchase - Stock Titan
Zai Lab (NASDAQ:ZLAB) Given New $32.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) - ChartMill
Zai Lab (NASDAQ:ZLAB) CFO Sells $31,726.89 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) Insider Joshua Smiley Sells 1,966 Shares - MarketBeat
Zai Lab (NASDAQ:ZLAB) Insider Sells $55,088.91 in Stock - MarketBeat
Zai Lab (ZLAB) officer granted options, RSUs and sells ADSs for taxes - Stock Titan
Zai Lab (ZLAB) CLO awarded major option, RSU grants and sells ADSs for taxes - Stock Titan
Zai Lab (NASDAQ: ZLAB) officer gets major equity grants, sells ADSs for taxes - Stock Titan
Zai Lab (ZLAB) CEO receives large ADS option and RSU grants - Stock Titan
Assessing Zai Lab (ZLAB) Valuation After Prolonged Share Price Weakness And Reported Intrinsic Discount - Sahm
ZLAB (NASDAQ: ZLAB) notice: 1,281 ADS proposed sale on 03/13/2026 - Stock Titan
Rafael Amado sells ZLAB ADS; 10,787 and 10,000 shares reported (ZLAB) - Stock Titan
Zai Lab Ltd (ADR) Stock (ISIN: CA98959U1084) Faces Insider Selling Pressure Amid Earnings Anticipati - AD HOC NEWS
Finanzdaten der Zai Lab Limited Adr-Aktie (ZLAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zai Lab Limited Adr-Aktie (ZLAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Edmondson Frazor Titus III | Chief Legal Officer |
Apr 02 '26 |
Sale |
20.39 |
4,194 |
85,516 |
24,590 |
| Du Ying | Chairperson & CEO |
Apr 02 '26 |
Sale |
20.39 |
5,576 |
113,695 |
1,125,279 |
| Chen Yajing | Chief Financial Officer |
Apr 02 '26 |
Sale |
20.39 |
5,199 |
106,008 |
32,558 |
| Amado Rafael | See Remarks |
Apr 02 '26 |
Sale |
20.39 |
9,910 |
202,065 |
59,761 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):